Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ANPEP | P15144 | 1/20 | 0.48 |
| ▸ | S1PR4 | O95977 | 2/20 | 0.46 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 4/20 | 0.45 |
| ▸ | CTSK | P43235 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | NTSR1 | P30989 | 1/20 | 0.44 |
| ▸ | ATM | Q13315 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | RECQL | P46063 | 1/20 | 0.44 |
| ▸ | CAPN1 | P07384 | 1/20 | 0.44 |
| ▸ | BIRC2 | Q13490 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5869581 | 1.00 | ANPEP (0.48) | ANPEPS1PR4S1PR1MAPTCTSK | |
| SCHEMBL10421048 | 0.82 | CTSK (0.60) | S1PR4S1PR1MAPTCTSK | |
| SCHEMBL8248870 | 0.82 | ANPEP (0.55) | ANPEPCAPN1BIRC2 | |
| SCHEMBL8437490 | 0.81 | TAS1R3 (0.42) | ANPEPALDH1A1NPSR1BIRC2 | |
| SCHEMBL7480048 | 0.81 | ANPEP (0.45) | ANPEPS1PR4S1PR1MAPTCTSK | |
| SCHEMBL5870299 | 0.81 | RAB9A (0.46) | ANPEPMAPTCTSKALDH1A1ATM | |
| SCHEMBL5869967 | 0.81 | ANPEP (0.45) | ANPEPS1PR4S1PR1MAPTCTSK | |
| SCHEMBL5869690 | 0.80 | ANPEP (0.50) | ANPEPCTSKCAPN1BIRC2 | |
| SCHEMBL5869470 | 0.80 | ANPEP (0.50) | ANPEPCTSKCAPN1BIRC2 | |
| SCHEMBL5869462 | 0.80 | ANPEP (0.50) | ANPEPCTSKCAPN1BIRC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040082496-A1 | ACE-2 modulating compounds and methods of use thereof | MILLENNIUM PHARMACEUTICALS, INC. | 2004-04-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040082496-A1 | ACE-2 modulating compounds and methods of use thereof | ACE, ACE2, AGTR2 | ANPEP 118/4885S1PR4 2291/4885S1PR1 2262/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.